Recent Comments

Comment RSS

Abacavir News and Research RSS Feed - Abacavir News and Research

Abacavir sulfate, also known as Ziagen or ABC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself.

Applications of pharmacogenomics in drug development

28. October 2009 06:17
Reportlinker.com announces that a new market research report is available in its catalogue: Reportlinker Adds Pharmacogenomics: Delivering on the Promise [More]

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

14. September 2009 06:26
ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK. [More]

GlaxoSmithKline pledges $97 million investment in AIDS drugs for Africa, allows South African drugmaker to produce generic second-line treatment

15. July 2009 18:05
GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports. [More]

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , ,

Genetic screening effective for initial HIV treatment

17. September 2008 19:41
A major study from a team of researchers from Weill Cornell Medical College and Massachusetts General Hospital has found that a recent change to HIV-treatment guidelines recommending genetic screening is cost-effective under certain conditions. The new recommendation suggests conducting a genetic screening test prior to prescribing the drug abacavir, one of the preferred first-line drugs for the treatment for HIV-infected adults. [More]

Posted in: Medical Research News

Tags: , , , , , ,

HIV drugs, Abacavir and Didanosine increase the risk of heart attack

8. February 2008 06:46
A study to assess the adverse effects of anti-retroviral drugs shows that two widely-used HIV drugs are associated with an increased risk of heart attack/the formation of blood clots in the heart. [More]

Public standards for world medications to treat neglected infectious diseases

29. January 2007 12:48
The United States Pharmacopeia (USP) has released free documentary standards for medicines used outside the United States to treat neglected infectious diseases. [More]

Posted in: Disease/Infection News

Tags: , , ,

FDA gives tentative approval for generic pediatric AIDS drug

27. June 2006 18:31
The Food and Drug Administration (FDA) today announced the tentative approval of the generic version of Abacavir Sulfate Oral Solution. [More]

FDA gives tentative approval to new generic AIDS drug

18. May 2006 19:17
The Food and Drug Administration (FDA) today announced the tentative approval of generic abacavir sulfate tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

Clinton's deal with drug companies will save millions of lives and millions of dollars

16. January 2006 04:30
Former U.S. President Bill Clinton has struck a deal with nine drug companies to reduce the cost of the second-line AIDS drugs. [More]

Posted in: Disease/Infection News

Tags: , , , , ,

States to explore putting restrictions on AIDS drug Trizivir

6. January 2005 05:47
AIDS Healthcare Foundation (AHF) has sent a letter dated October 20, 2004, to the heads of all state Medicaid programs asking them put in use treatment authorization request (TAR) procedures on GlaxoSmithKline's (GSK) fixed-dose combination AIDS drug, Trizivir, as a standalone regimen for treatment naïve patients. [More]

Posted in: Pharmaceutical News

Tags: , , , ,

Approval of fixed-dose combination treatments for HIV-1 infection

5. August 2004 08:11
The Food and Drug Administration has announced the approvals of Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

FDA approves two fixed-dose combination treatments for HIV-1 infection

2. August 2004 19:34
The Food and Drug Administration has announced approved Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.